Although it is unlikely that KMT2C will prove to be the only histone modifier that regulates ERα function, the findings in this report suggest it to be a key regulator of the estrogen responsive phenotype with major implications for hormone therapy of breast cancer. Here, KMT2C is linked to breast cancer.